Wai-Kay Seto

Wai-Kay Seto

Auto-generated profile, based on publicly available information

Wai-Kay Seto

Department of Medicine, Queen Mary Hospital, The University of Hong Kong, Hong Kong, China

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 October 2017 in Alimentary Pharmacology & Therapeutics
Verified
Journal Article
Open access
PDF file
LMLung-Yi Loey Mak
Lung-Yi Loey Mak
DWD. K.‐H. Wong
D. K.‐H. Wong
KCKa Shing Cheung
Ka Shing Cheung
WSW.‐K. Seto
W.‐K. Seto
Ching-Lung LaiChing-Lung Lai
Ching-Lung Lai
MYMan-Fung Yuen
Man-Fung Yuen
Summary: Background: Chronic hepatitis B (CHB) cannot be completely eradicated due to the presence of covalently closed circular DNA (cccDNA) in the nuclei of infected hepatocytes. While quantification of intrahepatic cccDNA requires liver biopsies, serological markers can be non‐invasive alternatives to reflect intrahepatic viral replicative activity. Recently, hepatitis B core‐related antigen (HBcrAg) has been advocated as a novel serum marker for disease monitoring and prognostication of CHB.Aim: To examine the virological aspect and clinical application of HBcrAg with respect to the natural history and treatment of CHB.Methods: We reviewed all papers published in the PubMed journal list and abstracts from major international meetings that included the keyword “HBcrAg” or “hepatitis B core‐related antigen” until March 2017. Selected studies were compared and summarised on the basis of existing theories, as well as the authors’ experience.Results: HBcrAg exhibited good correlation with intrahepatic (ih) cccDNA, ih total hepatitis B virus (HBV) DNA, serum HBV DNA and to a lesser extent HBV surface antigen (HBsAg). In situations where serum HBV DNA levels become undetectable or HBsAg loss is achieved, HBcrAg can still be detectable. This marker is helpful in differentiation of HBeAg‐negative chronic hepatitis from HBeAg‐negative chronic infection, predicting spontaneous or treatment‐induced HBeAg seroconversion, sustained response to nucleos(t)ide analogue (NA), risk of HBV reactivation in occult HBV infection under immunosuppressive therapies, and risk of hepatocellular carcinoma (HCC) development as well as post‐operative HCC recurrence.Conclusions: HBcrAg is a potential surrogate marker of cccDNA. It may soon become a useful marker for disease monitoring, predicting treatment response and disease outcome of chronic hepatitis B.

4 March 2020 in Alimentary Pharmacology & Therapeutics
Verified
Journal Article
Open access
PDF file
CEChris Estes
Chris Estes
HCHenry L. Y. Chan
Henry L. Y. Chan
RCRong N. Chien
Rong N. Chien
WCWan‐Long Chuang
Wan‐Long Chuang
JFJames Fung
James Fung
HRHomie Razavi
Homie Razavi
Summary: Background: Non‐alcoholic fatty liver disease (NAFLD) and non‐alcoholic steatohepatitis (NASH) account for an increasing proportion of liver disease in the Asia‐Pacific region. Many areas in the region are experiencing epidemics of metabolic syndrome among rapidly ageing populations.Aims: To estimate using modelling the growth in NAFLD populations, including cases with significant fibrosis that are most likely to experience advanced liver disease and related mortality.Methods: A disease progression model was used to summarise and project fibrosis progression among the NAFLD populations of Hong Kong, Singapore, South Korea and Taiwan. For each area, changes in the adult prevalence of obesity was used to extrapolate long‐term trends in NAFLD incidence.Results: In the areas studied, prevalent NAFLD cases were projected to increase 6%‐20% during 2019‐2030, while prevalent NASH cases increase 20%‐35%. Incident cases of hepatocellular carcinoma are projected to increase by 65%‐85%, while incident decompensated cirrhosis cases increase 65%‐100% by 2030. Likewise, NAFLD‐related mortality is projected to increase between 65% and 100% from 2019 to 2030. NAFLD disease burden is expected to increase alongside rising trends in metabolic syndrome and obesity among populations in the region. This leads to more cases of advanced liver disease and associated mortality.Conclusions: Preventing the growth of diabetic and obese populations will be a key factor in reducing ongoing increases in NAFLD‐related disease burden in the Asia‐Pacific region.

1 October 2020 in Journal of Hepatology
Verified
Journal Article
Closed access
LMLung-Yi Loey Mak
Lung-Yi Loey Mak
RHRex Wan-Hin Hui
Rex Wan-Hin Hui
JFJames Fung
James Fung
FLFen Liu
Fen Liu
DWDanny Wong
Danny Wong
WSWai-Kay Seto
Wai-Kay Seto

3 August 2017 in Journal of Viral Hepatitis
Verified
Journal Article
Closed access
PDF file
RHR. W. H. Hui
R. W. H. Hui
WSW.‐K. Seto
W.‐K. Seto
KCKa Shing Cheung
Ka Shing Cheung
LMLung-Yi Loey Mak
Lung-Yi Loey Mak
KLK. S. H. Liu
K. S. H. Liu
MYMan-Fung Yuen
Man-Fung Yuen

18 January 2022 in The Lancet Global Health
Verified
Journal Article
Open access
SSShu Su
Shu Su
WWWilliam Cw Wong
William Cw Wong
ZZZhuoru Zou
Zhuoru Zou
DCDan Dan Cheng
Dan Dan Cheng
JOJason J Ong
Jason J Ong
LZLei Zhang
Lei Zhang
China has the highest prevalence of hepatitis B virus (HBV) infection worldwide. Universal HBV screening might enable China to reach the WHO 2030 target of 90% diagnostics, 80% treatment, and 65% HBV-related death reduction, and eventually elimination of viral hepatitis. We evaluated the cost-effectiveness of implementing universal HBV screening in China and identified optimal screening strategies. We used a Markov cohort model, inputting parameters based on data from previous studies and public databases, to assess the cost-effectiveness of four HBV serological screening strategies in China in different screening scenarios. We simulated universal screening scenarios in 15 adult age groups between 18 and 70 years, with different years of screening implementation (2021, 2026, and 2031) and compared to the status quo (ie, no universal screening); in total, we investigated 180 different screening scenarios. We calculated the incremental cost-effectiveness ratio (ICER) between the different screening strategies and the status quo (current screening strategy). We performed probabilistic and one-way deterministic sensitivity analyses to assess the robustness of our findings. With a willingness-to-pay level of three times the Chinese gross domestic product (GDP) per capita (US$30 828), all universal screening scenarios in 2021 were cost-effective compared with the status quo. The serum HBsAg/HBsAb/HBeAg/HBeAb/HBcAb (five-test) screening strategy in people aged 18–70 years was the most cost-effective strategy in 2021 (ICER $18 295/quality-adjusted life-years [QALY] gained). This strategy remained the most cost-effective, when the willingness-to-pay threshold was reduced to 2 times GDP per capita. The two-test strategy for people aged 18–70 years became more cost-effective at lower willingness-to-pay levels. The five-test strategy could prevent 3·46 million liver-related deaths in China over the lifetime of the cohort. It remained the most cost-effective strategy when implementation was delayed until 2026 (ICER $20 183/QALY) and 2031 (ICER $23 123/QALY). Screening young people (18–30 years) will no longer be cost-effective in delayed scenarios. The five-test universal screening strategy in people aged 18–70 years, implemented within the next 10 years, is the optimal HBV screening strategy for China. Other screening strategies could be cost-effective alternatives, if budget is limited in rural areas. Delaying strategy implementation reduces overall cost-effectiveness. Early screening initiation will aid global efforts in achieving viral hepatitis elimination. National Natural Science Foundation of China.

31 March 2017 in Hepatology
Verified
Journal Article
Open access
PDF file
JFJames Fung
James Fung
TWTiffany Wong
Tiffany Wong
KCKenneth Siu Ho Chok
Kenneth Siu Ho Chok
ACAlbert Chi-Yan Chan
Albert Chi-Yan Chan
TCTan‐To Cheung
Tan‐To Cheung
CLChung‐Mau Lo
Chung‐Mau Lo
Long‐term antiviral prophylaxis is required to prevent hepatitis B recurrence for patients with chronic hepatitis B after liver transplantation. We determined the long‐term outcome of 265 consecutive chronic hepatitis B liver transplant recipients treated with entecavir monotherapy without hepatitis B immune globulin. Viral serology, viral load, and liver biochemistry were performed at regular intervals during follow‐up. The median duration of follow‐up was 59 months. The cumulative rates of hepatitis B surface antigen (HBsAg) seroclearance were 90% and 95% at 1 and 5 years, respectively. At 1, 3, 5, and 8 years, 85%, 88%, 87.0%, and 92% were negative for HBsAg, respectively, and 95%, 99%, 100%, and 100% had undetectable hepatitis B virus (HBV) DNA, respectively. Fourteen patients remained persistently positive for HBsAg, all of whom had undetectable HBV DNA. There was no significant difference in liver stiffness for those who remained HBsAg‐positive compared to those who achieved HBsAg seroclearance (5.5 versus 5.2 kPa, respectively; P = 0.52). The overall 9‐year survival was 85%. There were 37 deaths during the follow‐up period, of which none were due to hepatitis B recurrence. Conclusion: Long‐term entecavir monotherapy is highly effective at preventing HBV reactivation after liver transplantation for chronic hepatitis B, with a durable HBsAg seroclearance rate of 92%, an undetectable HBV DNA rate of 100% at 8 years, and excellent long‐term survival of 85% at 9 years. (Hepatology 2017;66:1036‐1044).